Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: An update from the German Hodgkin's Lymphoma Study Group (GHSG).

被引：0
|
作者：
Schulz, H
Rehwald, U
Reiser, M
Ruediger, T
Morschhauser, F
Diehl, V
Engert, A
机构：
[1] Univ Cologne, Dept Internal Med 1, D-5000 Cologne 41, Germany
[2] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[3] Ctr Hosp Reg & Univ Lille, F-59037 Lille, France
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3066
引用
收藏
页码：775A / 775A
页数：1
相关论文
共 50 条
  • [31] Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Yang, J.
    Li, Z.
    Zhang, M.
    Zhou, K.
    Li, Y.
    Yang, Y.
    Wang, Z.
    Yu, L.
    Zhang, J.
    Huang, H.
    Cheng, Y.
    Meng, W.
    Wang, Z.
    Lu, Q.
    Tian, W.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2024, 35 : S610 - S610
  • [32] Hodgkin lymphoma in adolescents treated with adult protocols: An analysis from the German Hodgkin Study Group (GHSG)
    Eichenauer, D. A.
    ONKOLOGIE, 2010, 33 : 9 - 9
  • [33] Hodgkin's lymphoma and chronic fatigue: longitudinal study conducted by the German Study Group Hodgkin's lymphoma
    Gruchet, Cecile
    Cayssials, Emilie
    Leleu, Xavier
    Guidez, Stephanie
    Hematologie, 2016, 22 (06): : 389 - 389
  • [34] Treatment-related mortality in patients undergoing therapy for advanced Hodgkin's Lymphoma: Analysis of the German Hodgkin Study Group (GHSG)
    Wongso, D.
    Pluetschow, A.
    Fuchs, M.
    Haverkamp, H.
    Klimm, B.
    Sasse, S.
    Diehl, V
    Borchmann, P.
    Engert, A.
    ONKOLOGIE, 2012, 35 : 169 - 170
  • [35] TREATMENT-RELATED MORTALITY IN PATIENTS UNDERGOING THERAPY FOR ADVANCED HODGKIN'S LYMPHOMA: ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG)
    Wongso, D.
    Pluetschow, A.
    Fuchs, M.
    Haverkamp, H.
    Klimm, B.
    Sasse, S.
    Diehl, V.
    Engert, A.
    Borchmann, P.
    HAEMATOLOGICA, 2012, 97 : 457 - 457
  • [36] Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG)
    Eichenauer, Dennis A.
    Bredenfeld, Henning
    Franklin, Jeremy
    Haverkamp, Heinz
    Mueller, Horst
    Eich, Hans T.
    Mueller, Rolf-Peter
    Fuchs, Michael
    Borchmann, Peter
    Diehl, Volker
    Engert, Andreas
    BLOOD, 2009, 114 (22) : 300 - 300
  • [37] A phase I study of 90Yttrium-lbritumomab-Tiuxetan in children and adolescents with Relapsed/Refractory CD20-positive non-Hodgkin's lymphoma:: A children's oncology group study
    Cooney-Qualter, Erin
    Krailo, Mark
    Angiolillo, Anne
    Fawwaz, Rashid A.
    Wiseman, Gregory
    Harrison, Lauren
    Kohl, Virginia
    Adamson, Peter C.
    Ayello, Janet
    vandeVen, Carmella
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5652S - 5660S
  • [38] Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
    Belada, D.
    Mayer, J.
    Czuczman, M. S.
    Flinn, I. W.
    Durbin-Johnson, B.
    Bray, G. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [40] Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Yuankai
    Yang, Jianliang
    Song, Yongping
    Zhou, Keshu
    Li, Zhiming
    Zhang, Mingzhi
    Jing, Hongmei
    Wang, Zhen
    Yu, Li
    Lu, Qiying
    Gan, Frank
    Tian, Wenzhi
    CANCER RESEARCH, 2024, 84 (07)
12345